We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account

COVID-19

Home » Topics » COVID-19
  • February 6, 2023

    Fate of 70+ FDA Guidances Hangs in the Balance as End of Public Emergency Approaches

    As the Biden administration prepares to end the COVID-19 public health emergency on May 11, the FDA must decide what to do with dozens of temporary guidances issued during the public health emergency.
  • February 6, 2023

    Medicago to Shut Down Despite COVID-19 Vaccine Approval

    The company had planned to develop vaccines for several other conditions, including seasonal flu, rotavirus and norovirus infections.
  • February 3, 2023

    FDA Updates Letters of Authorization for COVID Drugs Paxlovid and Lagevrio

    The updated authorizations were supported by data from late-stage studies.
Read More
  • January 10, 2023

    FDA Doubts Evusheld’s Efficacy Against New COVID-19 Variant

  • December 28, 2022

    FDA Approves Actemra for Hospitalized Adults with COVID-19

  • December 13, 2022

    Combination COVID-19/Flu Vaccine Gains Fast Track

  • December 12, 2022

    FDA Expands Authorization of Bivalent COVID-19 Vaccines to Young Children

  • December 2, 2022

    FDA Withdraws Authorization for Last Remaining COVID-19 Monoclonal Antibody Treatment

  • November 18, 2022

    NICE Rejects Five Treatments for COVID-19

  • November 11, 2022

    FDA Grants Sobi Emergency Authorization for Kineret to Treat COVID-19

  • November 4, 2022

    FDA Redefines Face-to-Face Meetings to Include Virtual Option

  • November 2, 2022

    FDA Clarifies Advertising and Marketing Rules for Certain COVID-19 Drugs

  • November 2, 2022

    Senzo Partners with BARDA over Amplified COVID-19 Antigen Test

Read More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing